Product Details

Uniprot No.

Target Names

CYP2D6

Alternative Names

Cytochrome P450 2D6 (EC 1.14.14.1) (CYPIID6) (Cholesterol 25-hydroxylase) (Cytochrome P450-DB1) (Debrisoquine 4-hydroxylase), CYP2D6, CYP2DL1

Species Reactivity

Human, Mouse, Rat

Immunogen

A synthesized peptide from human CYP2D6 protein

Immunogen Species

Homo sapiens (Human)

Conjugate

Non-conjugated

Clonality

Monoclonal

Isotype

Rabbit IgG

Clone No.

7B8

Purification Method

Affinity-chromatography

Concentration

It differs from different batches. Please contact us to confirm it.

Buffer

Rabbit IgG in 10mM phosphate buffered saline , pH 7.4, 150mM sodium chloride, 0.05% BSA, 0.02% sodium azide and 50% glycerol.

Form

Liquid

Tested Applications

ELISA, WB, IHC, IF, FC

Recommended Dilution

Application	Recommended Dilution
WB	1:500-1:2000
IHC	1:50-1:200
IF	1:50-1:200
FC	1:50-1:200

Protocols

ELISA Protocol
Western Blotting(WB) Protocol
Immunohistochemistry (IHC) Protocol
Immunofluorescence (IF) Protocol
Flow Cytometry (FC) Protocol

Troubleshooting and FAQs

Antibody FAQs

Storage

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Lead Time

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Description

Cytochrome P450 2D6 represents one of the most clinically significant drug-metabolizing enzymes in the human liver, responsible for the biotransformation of approximately 25% of commonly prescribed medications including antidepressants, antipsychotics, opioids, and cardiovascular drugs. Understanding CYP2D6 expression patterns and activity is essential for pharmacogenomics research, drug development studies, and investigations into individual variability in drug response and toxicity.

This recombinant monoclonal antibody, clone 7B8, offers researchers the reproducibility advantages inherent to sequence-defined antibody production. Because the antibody sequence is fixed and expressed in controlled systems, you can expect consistent performance across different lots, eliminating a common source of experimental variability that can complicate long-term studies or multi-site collaborations.

Validation testing demonstrates robust performance across multiple experimental platforms. Western blot analysis detects a band at the predicted 56 kDa molecular weight in human LO2 hepatocyte lysates as well as mouse and rat liver and colorectal tissue lysates, confirming cross-species reactivity that supports comparative metabolism studies and preclinical research models. Immunohistochemistry staining has been validated in both normal human liver tissue and liver cancer specimens, providing options for studying CYP2D6 expression in disease contexts. For cellular studies, immunofluorescence detection in HepG2 hepatocellular carcinoma cells reveals subcellular localization patterns, while flow cytometry analysis of the same cell line enables quantitative expression profiling at the single-cell level.

This antibody serves researchers investigating drug metabolism pathways, hepatotoxicity mechanisms, pharmacogenomic variability, and liver disease progression where altered CYP2D6 expression may influence therapeutic outcomes or disease phenotypes.

Usage

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

Related Products

Target Background

Function

A cytochrome P450 monooxygenase involved in the metabolism of fatty acids, steroids and retinoids. Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (NADPH--hemoprotein reductase). Catalyzes the epoxidation of double bonds of polyunsaturated fatty acids (PUFA). Metabolizes endocannabinoid arachidonoylethanolamide (anandamide) to 20-hydroxyeicosatetraenoic acid ethanolamide (20-HETE-EA) and 8,9-, 11,12-, and 14,15-epoxyeicosatrienoic acid ethanolamides (EpETrE-EAs), potentially modulating endocannabinoid system signaling. Catalyzes the hydroxylation of carbon-hydrogen bonds. Metabolizes cholesterol toward 25-hydroxycholesterol, a physiological regulator of cellular cholesterol homeostasis. Catalyzes the oxidative transformations of all-trans retinol to all-trans retinal, a precursor for the active form all-trans-retinoic acid. Also involved in the oxidative metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.

Gene References into Functions

prevalence of CYP2D6*4 1934AA genotype was higher in total HIV patients compared to healthy controls; similarly, CYP2D6*4 1934AA genotype was much more prevalent in HIV patients without hepatotoxicity compared to healthy controls; there was no significant difference in genotype or allele frequencies of CYP2D6*4 1934G/A polymorphism between the patients with hepatotoxicity and those without or healthy controls PMID: 30357957
CYP2D6 polymorphisms increase vulnerability to tramadol-induced hepatotoxicity. PMID: 29555325
Hot flash severity during tamoxifen therapy can not be accounted for by CYP2D6 genotype or observed plasma concentration of tamoxifen, 4-hydroxytamoxifen, or endoxifen PMID: 29980881
found a novel haplotype which involves 100C>T without 4180G>C PMID: 28606035
There was a significant difference in baseline neuropsychological scores among schizophrenia patients with three genotypes of CYP2D6 rs1135840. Also, rs1135840 showed a significant association with change in scores after risperidone treatment. This reflected a smaller change in GG genotype than C allele carriers; comparison of these two genotype groups gave a significant difference. PMID: 28131599
The ratio dehydro-aripiprazole/aripiprazole was influenced by CYP2D6 phenotype PMID: 29325225
In a cohort of schizophrenia inpatients CYP2D6 metabolic activity affects mean AP daily dose only in the presence of DRD2 Taq1A polymorphic allele. CYP2D6 metabolic activity correlates independently from DRD2 Taq1A polymorphism with hospital stay duration. Subpopulation of schizophrenia inpatients with altered CYP2D6 activity (PMs and UMs) carriers of Taq1A polymorphisms needs special attention of clinicians in aligning o PMID: 29930225
Dacomitinib total (AUCinf) and peak exposures (Cmax) were similar among subjects with different CYP2D6 genotypes. PMID: 28648122
CYP2D6*4 Polymorphism is associated with drug resistance in Breast Cancer. PMID: 29479969
Comparisons of pharmacokinetics of 25 substrates CYP2C9, CYP2C19, or CYP2D6 in healthy Chinese and European subjects (classified with same enzyme activity) suggest that, for most substrates, limited interethnic pharmacokinetic differences exist (according to the databases used in this study). (CYP2C9 = cytochrome P450 family 2 subfamily C member 9; CYP2C19 = cytochrome P450 family 2 subfamily C member 19) PMID: 29181698
TAM metabolism is extremely complex and involves several drug-metabolizing enzymes. Despite having shown a clear gene-exposure effect, CYP2D6 genotype can only partially explain the interindividual variability observed in TAM metabolite levels. PMID: 27698402
CYP2D6 polymorphisms were not associated with hypertension risk. PMID: 29549925
Results found significant association of C2850T, G1846A and C100T polymorphisms of CYP2D6 with coronary artery disease especially in females of North-West Indian population. PMID: 29660517
This population-based study does not support the hypothesis that patients with diminished CYP2D6 activity achieve inferior tamoxifen benefit. These contradictory findings suggest that the association between CYP2D6 genotype and tamoxifen treatment efficacy is null or near null, and unlikely to be useful in clinical practice. PMID: 28730340
The study results indicated the good response pattern was influenced by the concentration of donepezil, but not by APOE and CYP2D6 polymorphisms. PMID: 27716659
tamoxifen biotransformation to endoxifen is highly dependent on CYP2D6 activity; however, it is unclear whether there is an association between CYP2D6 genotype or endoxifen concentration and tamoxifen efficacy. PMID: 27249031
even though the available recommendations are against the CYP2D6 screening, the negative results of clinical trials may have been biased by issues in data collection, analysis and interpretation. PMID: 27883289
CYP2D6 protein and activity levels did not differ significantly between the genotypes (CYP2D6*1/*1, *1/*10, and *10/*10 genotypes) in the small intestine of the Japanese population. PMID: 28626197
genetic association studies in Chinese population: Data suggest that genetic polymorphisms and mutations in CYP2D6 are associated with alterations in metabolism of the anti-hemangioma medication hemangeol; some genetic alterations exclude hemangeol as a substrate for CYP2D6. PMID: 26542054
Genetic polymorphisms of some CYP enzymes, especially CYP2D6*10, could affect enzyme activity in hepatocellular carcinoma PMID: 27203676
This study demonstrates that the GSTP1*B and *C allelic variants may be considered a candidate gene for AD[Alzheimer disease]. It can be suggested that although CYP2D6*4 polymorphism is not a risk of AD[Alzheimer disease], the CYP2D6*4 and GSTP1 polymorphism may interact with beta-HCH, dieldrin, and copper to influence the risk of AD [Alzheimer disease]. PMID: 24584466
The number of functional CYP2D6 genes was positively associated with an increased risk of tardive dyskinesia, and suggest that this could be due to the generation of neurotoxic metabolites. PMID: 24595968
study found the 1846A allele frequency in Tatars was lower than in Russians, but the difference was not statistically significant; a statistically significant association between the development of extrapyramidal disorders (EPD) during haloperidol monotherapy and heterozygous 1846GA genotype and 1846A allele frequency was revealed among all schizophrenic patients and among those of Tatar ethnicity PMID: 27875318
The loss of function CYP2D6*3 (g.2549delA, rs35742686) genetic variant was found and contained the CYP2D6 g.2470T>C (rs17002852) variation, which had an allele frequency of 2.47%. PMID: 29073588
The CYP2D6 genotype may be potentially effective for predicting the response to donepezil treatment in Alzheimer's Disease patients. PMID: 27282366
We exploited CYP2D6 allele-frequency data that have been compiled for Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines .This comprehensive study summarizes allele frequencies, diplotypes, and predicted phenotype across major populations, providing a rich data resource for clinicians and researchers. Challenges of phenotype prediction from genotype data are highlighted and discussed. PMID: 27388693
In utero exposure to opioids is associated with increased DNA methylation of ABCB1, CYP2D6, and OPRM1 opioid-related genes in the newborn infant. PMID: 28867064
A total of 72 single nucleotide polymorphisms were identified. CYP2D6*1, *2, *4, *5, *10,*41, and duplication of the gene were found in the Orang Asli, whereby CYP2D6*2 and *41 alleles are reported for the first time in the Malaysian population PMID: 28525288
Data suggest that expression of CYP2D6 in hepatocytes is repressed by MIRN370 (hsa-miR-370-3p); MIRN370 represses expression of CYP2D6 even under the influence of CYP2D6 inducer (the glucocorticoid dexamethasone); the mechanism appears to involve the facilitation of CYP2D6 mRNA degradation. (CYP2D6 = cytochrome P450 family 2 subfamily D member 6; MIRN370 = microRNA 370) PMID: 28552654
Report predicted and measured CYP2D6 phenotype in a diverse South African population. PMID: 26503815
No association between cytochrome P450 CYP2D6 ultra-rapid metabolizer status and attempted suicide was observed in bivariate PMID: 27463022
Studied frequency of ADRB1 Arginine389Glycine (Arg389Gly) and Cytochrome p450 2D6*10 (Cyp2D6*10) polymorphism in cases of heart failure-reduced ejection fraction (HFREF), and to evaluate the influence of the polymorphisms in response to beta-blocker (BB) therapy; found a statistically significant association was observed with CC genotype and Glisin-Glisin (GG) genotype. PMID: 27665326
Variant genotypes of CYP2D6 are associated with an increased risk of esophageal squamous cell carcinoma in Kashmir, India. PMID: 28368717
genetic variation in CYP2D6 is a key predictor for the response to tamoxifen in patients with breast cancer PMID: 27797974
These results indicated that most of the allelic variants of CYP2D6 studied here, exhibited significantly decreased enzymatic activities towards methadone N-demethylation. PMID: 26968424
Evaluation of CYP2D6 ultrarapid metabolism should take into account activity of the multiplied alleles to avoid potential misclassification. PMID: 27272044
Of 830 patients with sickle cell disease, 621 (75%) had a CYP2D6 genotype result; 7.1% were ultra-rapid or possible ultra-rapid metabolizers, and 1.4% were poor metabolizers. PMID: 27335380
The purpose of this study was to determine the magnitude of effect of CYP2D6 genotype (activity score) on the dose-exposure relationship for ATX and its metabolites in children and adolescents with ADHD. PMID: 26660002
The kinetic parameters Km , Vmax and intrinsic clearance (Vmax /Km ) of N-desmethyltamoxifen were determined using CYP2D6 variants found in Chinese Han population. PMID: 27109434
present data in vitro suggest that the newly found variants significantly reduced catalytic activities compared with CYP2D6.1; given that CYP2D6 protein activities could affect carvedilol plasma levels, these findings are greatly relevant to personalized medicine PMID: 27354764
this meta-analysis shows that CYP2D6 gene polymorphisms are associated with susceptibility to autoimmune diseases in Caucasians PMID: 27749127
CYP2D6 polymorphisms were associated with decreased rates of pharmacokinetics and pharmacodynamics of 3,4-methylene-dioxymethamphetamine. PMID: 27253829
CYP2D6(*)10 mutations affect the pharmacokinetics of iloperidone and its metabolites in Chinese schizophrenia patients, suggesting that the clinical doses of iloperidone for patients with CYP2D6(*)10 mutations need to be optimized. PMID: 27665849
This study assess the catalytic activities of 24 CYP2D6 alleles variants toward tolterodine in vitro. There are 8 variants which showed altered catalytic activity toward tolterodine. PMID: 28087463
CYP2D6 polymorphisms were associated with the formation of O-desmethyl gefitinib from gefitinib. PMID: 27154635
allele were found to be related to the susceptibility to organophosphate chronic toxicity in Egyptians. PMID: 26723569
Olanzapine clearance was not affected by CYP2D6 or FMO3 genotypes or smoking behavior as a single factor under the present conditions because olanzapine clearance is mediated by multiple enzymes involved in two major and one minor pathways PMID: 26856397
Individual differences in metabolic clearance of risperidone under the present conditions were not significantly influenced by the genotypes of CYP2D6 or CYP3A5 PMID: 26856541
The multiplex SNaPshot method allows for specific and accurate detection of CYP2D6 genotypes and ADRB1 genotypes and haplotypes. This platform is simple and efficient and suited for high throughput. PMID: 27108086
CYP2D6 variants affect bufuralol and dextromethorphan in a Chinese population PMID: 26310775

Hide All

Subcellular Location

Endoplasmic reticulum membrane; Peripheral membrane protein. Microsome membrane; Peripheral membrane protein.

Protein Families

Cytochrome P450 family

Database Links

HGNC: 2625

OMIM: 124030

KEGG: hsa:1565

STRING: 9606.ENSP00000353820

UniGene: Hs.648256

Message

Product >> Product Name：
Product >> Code：
Name： *
Email： *
Company/Organization：
Phone：
Since emails may get flagged by spam filters occasionally, we recommend leaving your phone number as a precaution. Your information is safe with us.
Question/Comment： *
Your Region： *
I'd like to receive email newsletters from Cusabio

Yes

No
How do you know CUSABIO?

Email

Distributor

Search engine

Advertisement

Others
CAPTCHA verification：
Please enter the characters shown. Click the image to refresh if unclear.

Code	CSB-RA234050A0HU
Size	US$210
	Order now
Image	Western Blot Positive WB detected in: LO2 whole cell lysate(30µg), Mouse liver tissue lysate(30µg)), Rat liver tissue lysate(30µg)), Mouse colorectal tissue lysate(30µg)), Rat colorectal tissue lysate(30µg) All lanes: Cytochrome P450 2D6 antibody at 1:1000 Secondary Goat polyclonal to rabbit IgG at 1/40000 dilution Predicted band size: 56 kDa Observed band size: 56 kDa Exposure time：20s IHC image of CSB-RA234050A0HU diluted at 1:100 and staining in paraffin-embedded human liver cancer performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a Goat anti-rabbit polymer IgG labeled by HRP and visualized using 0.05% DAB. IHC image of CSB-RA234050A0HU diluted at 1:100 and staining in paraffin-embedded human liver tissue performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a Goat anti-rabbit polymer IgG labeled by HRP and visualized using 0.05% DAB. Immunofluorescence staining of HepG2 cell with CSB-RA234050A0HU at 1:50, counter-stained with DAPI. The cells were fixed in 4% formaldehyde, permeabilized using 0.2% Triton X-100 and blocked in 10% normal Goat Serum. The cells were then incubated with the antibody overnight at 4°C. The secondary antibody was Alexa Fluor 488-congugated AffiniPure Goat Anti-Rabbit IgG(H+L). Overlay Peak curve showing HepG2 cells stained with CSB-RA234050A0HU (red line) at 1:100. The cells were fixed in 4% formaldehyde and permeated by 0.2% TritonX-100 for 10min. Then 10% normal goat serum to block non-specific protein-protein interactions followed by the antibody (1ug/110⁶cells) for 45min at 4℃. The secondary antibody used was FITC-conjugated goat anti-rabbit IgG (H+L) at 1/200 dilution for 35min at 4℃.Control antibody (green line) was Rabbit IgG (1ug/110⁶cells) used under the same conditions. Acquisition of >10,000 events was performed.
Have Questions?	Leave a Message or Start an on-line Chat

CYP2D6 Recombinant Monoclonal Antibody

Product Details

Related Products

Customer Reviews and Q&A

Target Background